Technical Analysis for GMAB - Genmab A/S

Grade Last Price % Change Price Change
D 29.69 -0.84% -0.25
GMAB closed down 0.84 percent on Monday, March 18, 2024, on 59 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Multiple of Ten Bearish Other -0.84%
Overbought Stochastic Strength -0.84%
Down 3 Days in a Row Weakness -0.84%
Down 4 Days in a Row Weakness -0.84%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 15 hours ago
Fell Below Previous Day's Low about 15 hours ago
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
Down 2 % 4 days ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Genmab A/S Description

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.


Classification

Sector: Healthcare
Industry: Long-Term Care Facilities
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Drugs Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Genetics Acute Myeloid Leukemia Parkinson's Disease Immunotherapies Non Small Cell Lung Cancer Multiple Myeloma Multiple Sclerosis Orphan Drug Breakthrough Therapy Amyloid Amyloidosis Antibody Drug Conjugate Chronic Lymphocytic Leukemia Lymphocytic Leukemia Advanced Cancer Camidanlumab Tesirine Cd20 Copenhagen Treatment Of Chronic Lymphocytic Leukemia Advanced Cancers Genmab Solid Cancers

Is GMAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 42.995
52 Week Low 26.32
Average Volume 695,203
200-Day Moving Average 33.70
50-Day Moving Average 29.14
20-Day Moving Average 29.48
10-Day Moving Average 30.17
Average True Range 0.76
RSI (14) 51.46
ADX 19.91
+DI 34.42
-DI 26.44
Chandelier Exit (Long, 3 ATRs) 29.61
Chandelier Exit (Short, 3 ATRs) 29.78
Upper Bollinger Bands 31.61
Lower Bollinger Band 27.34
Percent B (%b) 0.55
BandWidth 14.49
MACD Line 0.45
MACD Signal Line 0.35
MACD Histogram 0.1038
Fundamentals Value
Market Cap 19.39 Billion
Num Shares 653 Million
EPS 0.94
Price-to-Earnings (P/E) Ratio 31.59
Price-to-Sales 1.07
Price-to-Book 4.04
PEG Ratio 1.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.20
Resistance 3 (R3) 30.25 30.13 30.12
Resistance 2 (R2) 30.13 30.00 30.11 30.09
Resistance 1 (R1) 29.91 29.92 29.85 29.86 30.06
Pivot Point 29.79 29.79 29.76 29.77 29.79
Support 1 (S1) 29.57 29.66 29.51 29.52 29.32
Support 2 (S2) 29.45 29.58 29.43 29.29
Support 3 (S3) 29.23 29.45 29.27
Support 4 (S4) 29.18